GeNeuro

News

GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting

HERV Approach

GeNeuro is pursuing a novel approach for treating autoimmune diseases by seeking to block mechanisms suspected of participating to their onset and development.